Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Keytruda pembrolizumab Primary mediastinal B-cell lymphoma Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Keytruda Pembrolizumab classical Hodgkin Lymphoma (cHL) Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab MUC First line Do not reimburse Complete
Keytruda Pembrolizumab Squamous NSCLC Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab Advanced non-small cell lung carcinoma (first line) Reimburse with clinical criteria and/or conditions Complete
Keytruda Pembrolizumab For locally advanced or metastatic urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Advanced or recurrent endometrial carcinoma Pending